Description Results NMA

all cause death or hospitalisation 0.91 [0.16; 5.30]

NYHA class improvement ∞ [NaN; ∞]

cilazapril (n=11)

vs.

placebo (n=10)

double blind

Sample size: 11/10

Primary endpoint:

FU duration: 3 months

cilazapril titrated up to 2.5 mg/d (n=7)

vs.

placebo (n=35)

double blind

Sample size: 7/35

Primary endpoint: exercise tolerance

FU duration: 12 weeks

cilazapril 1-2.5 mg once daily (n=221)

vs.

placebo (n=114)

double blind

Parallel groups

Sample size: 221/114

Primary endpoint: exercise tolerance

FU duration: 12 weeks

cilazapril 1-2.5 mg once daily (n=221)

vs.

captopril 25-50mg three times daily (n=108)

double blind

Parallel groups

Sample size: 221/108

Primary endpoint: exercise tolerance

FU duration: 12 weeks